Organizational Statements, Extending the Patent Term for Drugs Undergoing FDA Review During the Enactment of Hatch-Waxman

This page lists statements and information concerning the issue taken from the web sites of various organizations, trade associations, and interest groups involved in the issue. We provide both a link to the main page of the organization concerned as well as a copy of the pages relating to the issue that we found in our searches. Because we want to keep information concerning each of our cases for an archive, we copied their pages during the period of research. Below each statement is the original URL from which we retrieved the information. Note that some of these original URLs may not work because the group has updated or changed its website.

External Links to:

• Biotechnology Industry Organization
• Generic Pharmaceutical Industry Association
• International Union (UAW)
• National Association of Pharmaceutical Manufacturers
• National Organization for Rare Disorders
• National Pharmaceutical Alliance
• Patients and Consumers Coalition
  • AIDS Action Committee
  • Consumer Federation of America
  • Public Citizen
• Pharmaceutical Research and Manufacturers of America
• Schering-Plough

Internal Archive for the Biotechnology Industry Organization, downloaded on 2/7/01:

• No documents found

Internal Archive for the Generic Pharmaceutical Industry Association, downloaded on 2/7/01:

• No website found

Internal Archive for the International Union (UAW), downloaded on 2/7/01:

• Drugs Lead the Cost Increase (http://www.uaw.org/cap/01/issue/issue05-2.html)
• Stretching Our Dollars Further: Access to Generic Drugs (http://www.uaw.org/cap/2000/issues/issue12_4.html)

Internal Archive for the National Association of Pharmaceutical Manufacturers, downloaded on 1/30/01:

*Note: since this group no longer has a functioning homepage, we no longer provide the original URLs

• Brand Name Drug Companies Efforts to Extend their Pharmaceutical Monopolies: State Substitution Laws and Narrow Therapeutic Index Drugs
• Drug Patent Extension Will Cost Consumers $11 Billion, Says Prime Institute Report
• Hatch-Waxman Works, Don't Mess with Success
• Issues Affecting the Generic Drug Industry
• Keynote Address, NAPM Annual Conference, 1/31/00
• NAPM President Addresses the NAPM Midyear Conference
• NAPM Testimony to Senate Judiciary Committee Condemns Drug Patent Extensions
• NAPM Urges Congress to Reject Patent Extensions that Would Cost American Consumers Billions of Dollars
• Senator Tim Johnson Calls for Increased Access to Generic Pharmaceuticals
• Summary of Federal Laws with Particular Effects on the U.S. Generic Drug Industry

Internal Archive for the National Pharmaceutical Alliance, downloaded on 1/30/01:

• No documents found

Internal Archive for the Patients and Consumers Coalition, downloaded on 1/30/01:

• No website found

Internal Archive for the Consumer Federation of America, downloaded on 1/30/01:

• Schumer/McCain Bill Will Stop Prescription Drugs Industry from Blocking Access to Cheap, Safe Generic Drugs (http://www.consumerfed.org/generic.pdf)

Internal Archive for Public Citizen, downloaded on 1/31/01:

• Aggressive Lobbying behind Clairitin Patent Extension Bill that Could Cost Consumers $1.6-3.2 Billion (http://www.citizen.org/press/pr-drugs2.htm)
• Letter to Chairman Burns and Ranking Member Murray (http://www.citizen.org/press/pr-drugs23a.htm)
• Can Schering-Plough's Aggressive Lobbying Buy a Clairitin a Patent Extension? (http://www.citizen.org/congress/drugs/factshts/patentextension/splobby.htm)
• Clairitin Patent Extension Bill: Don't Be Fooled by the "R&D Scare Card" (http://www.citizen.org/congress/drugs/factshts/patentextension/claritinRD.htm)
• Columbia University Patent Extension Opposed by Major Consumer and Health Groups (http://www.citizen.org/press/pr-drugs25.htm)
• Columbia University Patent Extension Would Cost Consumers, Open Floodgates for More Special Deals (http://www.citizen.org/press/pr-drugs20.htm)
• Consumers Denounce "Taxpayers' Billion-Dollar Gift to Schering-Plough Shareholders" (http://www.citizen.org/press/pr-drugs3.htm)
• D.C. Area Consumers Pay More for Prescription Drugs while Pharmaceutical Profits Soar (http://www.citizen.org/congress/drugs/statereports/washdc.html)
• Letter to Senators McCain and Durbin from Consumer Groups (http://www.citizen.org/congress/drugs/letters/letter052300.htm)
• Letter to the Senate from Consumer Advocacy Groups Urging the Striking of Section 2801 (http://www.citizen.org/congress/drugs/letters/letter071800.htm)
• Massachusetts Consumers Pay More for Prescription Drugs while Pharmaceutical Profits Soar (http://www.citizen.org/congress/drugs/statereports/massachusetts.html)
• Montana Senator Conrad Burns Must Exercise Leadership to Block Money Grabs by Schering-Plough (http://www.citizen.org/press/pr-drugs23.htm)
• New Jersey Consumers Pay More for Prescription Drugs while Pharmaceutical Profits Soar (http://www.citizen.org/congress/drugs/statereports/newjersey.html)
• Oppose the Columbia University Patent Extension (http://www.citizen.org/congress/drugs/letters/letter071900.htm)
• Prove It Isn't So, Senator Ashcroft (http://www.citizen.org/congress/drugs/factshts/patentextension/ashcroft.htm)
• Rx Industry Goes for KO (http://www.citizen.org/congress/drugs/factshts/campaign$.htm)
• Schering-Plough Plows Ahead with a High-Priced Lobbying Campaign for Clairitin Special Patent Extension (http://www.citizen.org/press/pr-drugs5.htm)
• Schering-Plough Political Money Pushes Clairitin Patent Extension (http://www.citizen.org/congress/drugs/factshts/patentextension/plough$.htm)
• Schering-Plough Political Money Pushes Clairitin Patent Extension and Distorts GAO Report (http://www.citizen.org/press/pr-drugs26.htm)
• Schering-Plough Political Money Pushes Clairitin Patent Extension Bill onto Senate Judiciary Calendar (http://www.citizen.org/press/pr-drugs10.htm)
• Senate Judiciary Committee on November 17 on Special Interest Patent Extension for Clairitin (http://www.citizen.org/Press/pr-drugs11.htm)
• Seven Reasons to Vote NO on S.1172, Clairitin's Special Interest Patent Extension for Clairitin (http://www.citizen.org/congress/drugs/factshts/patentextension/claritin7.htm)
• Why the Pharmaceutical Industry's "R&D Scare Card" Does Not Justify High Drug Prices (http://www.citizen.org/congress/drugs/press/r&dscarecard.htm)

Internal Archive for AIDS Action Committee, downloaded on 2/7/01:

• No documents found

Internal Archive for Pharmaceutical Research and Manufacturing of America, downloaded on 2/7/01:

• The Changing Pharmaceutical Workplace (http://www.phrma.org/publications/publications/profile00/chap5.phtml)
• Global Intellectual Property Protection (http://www.phrma.org/publications/publications/profile00/chap8.phtml)
• Draft Guidance for Industry on Appliance Covered by Section 502(b)(2) Docket No. 99N-3088 (http://www.phrma.org/policy/drugdev/fdacomments/4-3-00.phtml)
• Market Exclusivity and Patent Provisions for Certain Antibiotic Drugs (http://www.phrma.org/policy/drugdev/fdacomments/4-24-00.phtml)
• Proposed Rule: 180-day Generic Drug Exclusivity for Abbreviated New Drug Applications (http://www.phrma.org/policy/drugdev/fdacomments/11-4-99.phtml)
• Response of Pharmaceutical Research and Manufacturing of America to the Citizen Petition of NAPM (http://www.phrma.org/policy/drugdev/fdacomments/12-14-99.phtml)
• Why Do Medicines Cost So Much? (http://www.phrma.org/publications/publications/brochure/questions/whycostmuch.phtml)

Internal Archive for Schering-Plough, downloaded on 2/7/01:

• No documents found